Table 4.
Clinical and molecular characteristics of BRAF mutant cancers with APC mutation.
| APC | p-Value 1 | |||||||
|---|---|---|---|---|---|---|---|---|
| Characteristic | n | Truncating Mutation | Missense Mutation | Wild-Type | Truncating vs. Missense | Truncating vs. Wild-Type | Missense vs. Wild-Type | |
| Mean Age | Years | 273 | 60.8 | 72.4 | 70.6 | 2.03 × 10−5 | 9.3 × 10−6 | 0.34 |
| Sex | Male | 87 (31.8%) | 18 (32%) | 6 (24%) | 63 (33%) | 0.48 | 0.86 | 0.36 |
| Female | 187 (68.2%) | 39 (68%) | 19 (76%) | 129 (67%) | ||||
| Tumour Side | Left | 42 (16.6%) | 13 (25%) | 1 (4%) | 28 (16%) | 0.02 | 0.16 | 0.08 |
| Right | 211 (83.4%) | 40 (75%) | 23 (86%) | 148 (84%) | ||||
| Stage | I | 32 (12.9%) | 3 (6%) | 2 (9%) | 27 (16%) | 0.01 | 0.002 | 0.32 |
| II | 93 (37.7%) | 14 (27%) | 12 (55%) | 67 (39%) | ||||
| III | 59 (23.9%) | 10 (19%) | 6 (27%) | 43 (25%) | ||||
| IV | 63 (25.5%) | 25 (48%) | 2 (9%) | 36 (21%) | ||||
| CIMP | High | 128 (81.0%) | 20 (83%) | 18 (95%) | 90 (78%) | 0.23 | 0.57 | 0.05 |
| Negative | 30 (19.0%) | 4 (17%) | 1 (5%) | 25 (22%) | ||||
| MSI | MSI | 136 (54.8%) | 22 (42%) | 21 (91%) | 93 (54%) | 5.3 × 10−5 | 0.14 | 0.0002 |
| MSS | 112 (45.2%) | 30 (58%) | 2 (9%) | 80 (46%) | ||||
1p-values were obtained using the likelihood–ratio test for categorical variables, and the Student’s t-test for continuous variables. All statistical analyses were two-tailed. Bold text indicates significance at p < 0.05